Participants are assigned at random to receive either ASP3082 plus chemotherapy or the placebo plus chemotherapy. The study drug is delivered by intravenous infusion, a process where the medication is slowly introduced into a vein. Treatment cycles are repeated every few weeks, and patients are monitored over several months for changes in tumor size, side effects, and overall health status before the study concludes.

The treatments being studied include belzutifan, which is taken as an oral film-coated tablet, and lenvatinib, which is taken as an oral capsule. Participants in the study will continue their current treatment regimen to monitor how the medications work over a longer period of time. The study will track overall survival, which refers to the length of time patients remain alive, and monitor any adverse events, which are side effects or unexpected medical problems that may occur during the treatment.

The purpose of this study is to compare the effectiveness of a new drug called daraxonrasib, also known by its code name RMC-6236, against the current standard of care, which involves close observation by medical professionals. Daraxonrasib is an oral medication taken in the form of a tablet.

During the study, participants are assigned to one of two groups through a process called randomization. One group will receive the experimental drug, while the other group will receive the standard observation. The course of the study involves monitoring patients over time to see how long they remain free from the disease and to track overall survival.

The purpose of the study is to find out if the new treatment is safe and to determine the best dose to use. Patients will receive the treatment through injections guided by ultrasound, a technique that uses sound waves to create images of the inside of the body. The study will start with a small dose of RR001 and gradually increase it to find the highest dose that can be given safely. The study will also look at how well the treatment works in shrinking the tumor and improving the patient’s quality of life.

Participants in the study will receive the treatment over a period of time and will be monitored closely by doctors. They will have regular check-ups, including imaging tests like CT scans to see how the tumor is responding to the treatment. The study will also track how long it takes for the disease to progress and how long patients live after receiving the treatment. The goal is to improve the outcomes for patients with this challenging type of cancer.

The purpose of this research is to understand how safe and effective AMG 193 is when used to treat patients with advanced solid tumors that lack the MTAP gene. The study is divided into multiple parts, with initial phases focusing on finding the right dose and checking how the body processes the medication, while later phases examine how well the treatment works in fighting the cancer.

During the study, participants will receive either AMG 193 alone or in combination with docetaxel. The treatment involves taking tablets by mouth. Throughout the study, doctors will monitor various aspects of the participants’ health and how their cancer responds to the treatment. They will track important measures such as tumor size changes and how long patients live without their disease getting worse.

Patients will receive treatment through intravenous infusion, which means the medications will be given directly into a vein. The medications will be administered in cycles over several months. During treatment, doctors will monitor how well the cancer responds and check for any side effects. The main goal is to measure how many patients have their cancer remain stable or improve after about 3 months of treatment.

The study will also track other important factors such as survival time, tumor response, and safety of the treatments. Researchers will collect blood and tissue samples to learn more about how the treatments work. The trial is expected to continue until late 2028.

The purpose of this study is to determine if this new imaging technique can help surgeons better see the cancer and surrounding tissues during surgery. The medication SGM-101 is designed to make the cancer cells glow under near-infrared light, which could help doctors better identify where the cancer has spread and determine if it can be completely removed during surgery. This imaging approach is being tested in patients who have already received initial treatment before surgery.

During the study, participants will receive a single dose of SGM-101 before their scheduled surgery. The maximum amount given will be 10 milligrams. During the operation, special cameras will be used to detect the areas where the medication makes the cancer cells visible. The study will also collect blood and tissue samples to better understand how well this imaging method works.

Participants in the study will receive either the combination of OSE2101 and FOLFIRI or FOLFIRI alone. The study will monitor the participants over a period to see how well they respond to the treatment and how long they live without the cancer getting worse. The study will also look at the side effects of the treatments and how they affect the participants’ quality of life. Some participants may receive a placebo as part of the study to help compare the effects of the actual treatments.

The trial is designed to help researchers understand if the combination of OSE2101 and FOLFIRI is more effective than FOLFIRI alone in treating this type of cancer. The study will involve regular check-ups and assessments, including imaging tests like CT scans, to track the progress of the disease and the impact of the treatment. The results of this study could provide valuable information for future treatment options for patients with pancreatic ductal adenocarcinoma.

The purpose of the study is to compare the effectiveness of the PAXG treatment to the mFOLFIRINOX treatment in terms of how long patients remain free from cancer progression. Participants in the study will receive either the short-course or long-course version of these treatments before undergoing surgery. The study will monitor the patients over a period of time to assess various outcomes, such as the response of the cancer to the treatment, the rate at which the cancer can be surgically removed, and the overall health and well-being of the patients during and after the treatment.

Throughout the study, patients will receive their treatments through intravenous infusions, which means the medication is delivered directly into the bloodstream through a vein. The study aims to provide valuable information on which treatment approach is more beneficial for patients with pancreatic ductal adenocarcinoma, potentially leading to improved treatment strategies in the future.

The purpose of the study is to compare the overall survival of patients who receive the combination of SBP-101, nab-paclitaxel, and gemcitabine with those who receive only nab-paclitaxel and gemcitabine. Participants will be randomly assigned to one of the two groups, and neither the participants nor the researchers will know who is receiving SBP-101 or the placebo. The study will involve regular visits to the clinic for treatment and monitoring, and participants will receive the medications through injections or infusions.

The study will continue for a period of time, during which the health and progress of the participants will be closely monitored. The main goal is to see if the addition of SBP-101 can improve the length of time patients live with this type of cancer. The study will also look at other factors, such as how long it takes for the cancer to progress and the overall response to the treatment. Participants will be asked to complete questionnaires about their quality of life during the study.

The purpose of the study is to evaluate the safety and effectiveness of these treatments. The study is divided into three parts. In the first part, participants will receive a single dose of Debio 0328 to assess its safety and how well it can help in imaging the tumors. In the second part, the study will determine the best dose of Debio 0228 for each type of cancer. The third part will explore the potential of Debio 0228 to reduce the size of the tumors. Some participants may receive a placebo, which is a substance with no active medication, to compare the effects of the treatments.

Throughout the study, participants will be closely monitored for any side effects and changes in their health. The study aims to gather information on how the body absorbs and processes these treatments, as well as their impact on the tumors. This research could provide valuable insights into new ways to treat these challenging cancers.

The purpose of the study is to understand how well MK-2870 works and how patients tolerate it. Participants will receive the treatment through an intravenous infusion, which means the medication is given directly into a vein. The study will monitor participants for any side effects and how their cancer responds to the treatment. Some participants may receive a placebo, which is a substance with no active medication, to compare the effects of the actual treatment.

Throughout the study, researchers will keep track of how long the treatment works, how long patients live without the cancer getting worse, and overall survival rates. The study aims to provide valuable information that could lead to better treatment options for people with these types of cancers. The trial is expected to continue until 2026, with recruitment starting in 2024.

The main purpose of this study is to evaluate how effective propranolol is in reducing anxiety before surgery and to observe any changes in the body’s response to the cancer. Additionally, the study will monitor heart rate variability, which is a measure of how the heart responds to stress, to see if propranolol has any impact. This information will help researchers understand the potential benefits of using propranolol in this context and guide future studies.

Throughout the study, the safety and tolerance of propranolol will be closely monitored by checking for any side effects, such as changes in heart rate or blood pressure. The study will also assess how practical it is to use propranolol in this way, considering factors like how easy it is for participants to take the medication and any barriers to its use. The results from this trial will provide valuable insights for designing larger studies in the future.